Drugs that contain Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Disoproxil Fumarate
1. List of Stribild drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(3 years from now) | |
| US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(3 years from now) | |
| US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(3 years from now) | |
| US8148374 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8592397 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(7 months from now) | |
| US8716264 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(7 months from now) | |
| US9457036 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(7 months from now) | |
| US9744181 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(7 months from now) | |
|
US7176220 (Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(3 years from now) | |
|
US8981103 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
|
US7635704 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
| US9891239 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(6 years from now) | |
|
US9891239 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(6 years from now) | |
|
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(6 years from now) | |
| US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(6 years from now) | |
|
US8633219 (Pediatric) | GILEAD SCIENCES INC | Combination therapy |
Oct, 2030
(7 years from now) | |
| US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) | |
|
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(9 years from now) | |
Market Authorisation Date: 27 August, 2012
Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET;ORAL
STRIBILD family patents
63
United States
34
Japan
34
European Union
22
Norway
15
Spain
15
Korea, Republic of
15
Australia
14
China
13
Portugal
12
Argentina
12
Croatia
12
Hungary
11
Denmark
11
Poland
11
Lithuania
11
Slovenia
10
Hong Kong
10
Cyprus
9
Canada
9
EA
9
New Zealand
9
Taiwan
8
Singapore
8
Mexico
7
Brazil
6
AP
6
RS
5
Ukraine
5
ME
5
Israel
5
South Africa
4
Peru
3
Luxembourg
2
Austria
2
Malaysia
2
Germany
2
Russia
2
Ecuador
2
Colombia
1
Uruguay
1
Turkey
1
Iceland
1
Czech Republic
1
San Marino
1
Chile
1
Netherlands
1
Slovakia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic